Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2012

01-09-2012 | Colorectal Cancer

Outcome of Patients with Colorectal Liver Metastasis: Analysis of 1,613 Consecutive Cases

Authors: Zhu Dexiang, MD, Ren Li, MD, Wei Ye, MD, PhD, Wu Haifu, MD, PhD, Zhong Yunshi, MD, PhD, Ye Qinghai, MD, PhD, Zhai Shenyong, MD, Xu Bo, MD, Liang Li, MD, Pan Xiangou, MD, Li Haohao, MD, Ye Lechi, MD, Liu Tianshu, MD, PhD, Fan Jia, MD, PhD, Qin Xinyu, MD, PhD, Xu Jianmin, MD, PhD

Published in: Annals of Surgical Oncology | Issue 9/2012

Login to get access

Abstract

Objective

This study was designed to evaluate the long-time outcome of patients with colorectal liver metastasis (CRLM) undergoing different types of therapy and identify prognosis factors.

Methods

From 2000 to 2010, 1,613 consecutive patients with CRLM were identified. Clinicopathological and outcome data were collected and analyzed by univariate and multivariate analyses.

Results

Synchronous liver metastasis (SLM), female, grade III-IV, T4 and N positive of primary tumor, bilobar disease, number of liver metastases ≥4, size of largest liver metastases ≥5 cm, serum CEA level ≥5 ng/ml, and CA19-9 level ≥37  u/ml were the predictors of adverse outcome using univariate analysis. The median survival and 5-year survival rate for patients after resection of liver metastases was 49.8 months and 47%, better than that for those after other therapy. In addition, patients without treatment had the poorest survival. Sixty-four initially unresectable patients underwent surgery after conversion therapy with a median survival of 36.9 months and a 5-year survival of 30%. By multivariate analysis, SLM, poorly differentiated primary tumor, number of liver metastases ≥4, size of largest liver metastases ≥5 cm, and no surgical treatment of liver metastases were found to be independent predictors of poor survival.

Conclusions

Patients with CRLM could get long-term survival benefit from different types of therapy, and resection of liver metastases was the optimal strategy. A predictive model using these above five factors may be of use in stratifying patients who may benefit from intensive surveillance and adjuvant therapy.
Literature
1.
Shanghai Municipal Center for Disease Control. Cancer incidence in Shanghai, 2007. Shanghai Preventive Med. 2010;22(7):400.
2.
Sharma S, Camci C, Jabbour N. Management of hepatic metastasis from colorectal cancers: an update. J Hepatobiliary Pancreat Surg. 2008;15(6):570–80.PubMedCrossRef
3.
Lewis AM, Martin RC. The treatment of hepatic metastases in colorectal carcinoma. Am Surg. 2006;72(6):466–73.PubMed
4.
Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–83.PubMedCrossRef
5.
Lochan R, White SA, Manas DM. Liver resection for colorectal liver metastasis. Surg Oncol. 2007;16(1):33–45.PubMedCrossRef
6.
Adam R, Hoti E, Bredt LC. Evolution of neoadjuvant therapy for extended hepatic metastases–have we reached our (non-resectable) limit? J Surg Oncol. 2010;102(8):922–31.PubMedCrossRef
7.
Xu J, Qin X, Wang J, et al. Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol. 2011;137(9):1379–96.PubMedCrossRef
8.
Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241(5):715–22.PubMedCrossRef
9.
Jaeck D. The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies. Ann Surg Oncol. 2003;10(9):1007–11.PubMedCrossRef
10.
Pulitanò C, Bodingbauer M, Aldrighetti L, et al. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol. 2011;18(5):1380–8.PubMedCrossRef
11.
Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20(6):985–92.PubMedCrossRef
12.
Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg. 2003;90(8):963–9.PubMedCrossRef
13.
Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16.PubMedCrossRef
14.
Chiappa A, Bertani E, Makuuchi M, et al. Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. Hepatogastroenterology. 2009;56(91-92):829–34.PubMed
15.
Gruenberger B, Scheithauer W, Punzengruber R, et al. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer. 2008;8:120.PubMedCrossRef
16.
Adam R, Bhangui P, Poston G, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg. 2010;252(5):774–87.PubMedCrossRef
17.
Chua TC, Saxena A, Liauw W, et al. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol. 2010;17(2):492–501.PubMedCrossRef
18.
Cleary JM, Tanabe KT, Lauwers GY, et al. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist. 2009;14(11):1095–105.PubMedCrossRef
19.
Gaujoux S, Goéré D, Dumont F, et al. Complete radiological response of colorectal liver metastases after chemotherapy: what can we expect? Dig Surg. 2011;28(2):114–20.PubMedCrossRef
20.
de Haas RJ, Adam R, Wicherts DA, et al. Comparison of simultaneous or delayed liver surgery for limited synchronous colorectal metastases. Br J Surg. 2010;97(8):1279–89.PubMedCrossRef
21.
Slupski M, Wlodarczyk Z, Jasinski M, et al. Outcomes of simultaneous and delayed resections of synchronous colorectal liver metastases. Can J Surg. 2009;52(6):E241–4.PubMed
22.
Moug SJ, Horgan PG. The role of synchronous procedures in the treatment of colorectal liver metastases. Surg Oncol. 2007;16(1):53–8.PubMedCrossRef
23.
Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27(20):3379–84.PubMedCrossRef
24.
Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg. 2010;34(4):797–807.PubMedCrossRef
25.
Karoui M, Roudot-Thoraval F, Mesli F, et al. Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study. Dis Colon Rectum. 2011;54(8):930–8.PubMedCrossRef
26.
Poston G, Adam R, Vauthey JN. Downstaging or downsizing: time for a new staging system in advanced colorectal cancer? J Clin Oncol. 2006;24(18):2702–6.PubMedCrossRef
27.
Nasti G, Ottaiano A, Berretta M, et al. Preoperative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. Cancer Chemother Pharmacol. 2010;66(2):209–18.PubMedCrossRef
28.
Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27(11):1829–35.PubMedCrossRef
29.
Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26(21):3523–9.PubMedCrossRef
30.
Vogl TJ, Zangos S, Eichler K, et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol. 2007;17(4):1025–34.PubMedCrossRef
31.
Mocellin S, Pilati P, Lise M, et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007;25(35):5649–54.PubMedCrossRef
32.
Stang A, Fischbach R, Teichmann W, et al. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer. 2009;45(10):1748–56.PubMedCrossRef
33.
Siperstein AE, Berber E, Ballem N, et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007;246(4):559–65.PubMedCrossRef
34.
House MG, Kemeny NE, Gönen M, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg. 2011;254(6):851–6.PubMedCrossRef
35.
Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996;77(7):1254–62.PubMedCrossRef
36.
Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18.PubMedCrossRef
37.
Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247(1):125–35.PubMedCrossRef
38.
Gomez D, Cameron IC. Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise? HPB (Oxford). 2010;12(4):227–38.
Metadata
Title
Outcome of Patients with Colorectal Liver Metastasis: Analysis of 1,613 Consecutive Cases
Authors
Zhu Dexiang, MD
Ren Li, MD
Wei Ye, MD, PhD
Wu Haifu, MD, PhD
Zhong Yunshi, MD, PhD
Ye Qinghai, MD, PhD
Zhai Shenyong, MD
Xu Bo, MD
Liang Li, MD
Pan Xiangou, MD
Li Haohao, MD
Ye Lechi, MD
Liu Tianshu, MD, PhD
Fan Jia, MD, PhD
Qin Xinyu, MD, PhD
Xu Jianmin, MD, PhD
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 9/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2356-9

Other articles of this Issue 9/2012

Annals of Surgical Oncology 9/2012 Go to the issue

Hepatobiliary Tumors

Diffuse Infiltrative Hepatocellular Carcinoma: Assessment of Presentation, Treatment, and Outcomes

Pancreatic Tumors

The Glasgow Prognostic Score as a Predictor of Survival in Patients with Potentially Resectable Pancreatic Adenocarcinoma

Colorectal Cancer

Clinicopathology and Outcomes for Mucinous and Signet Ring Colorectal Adenocarcinoma: Analysis from the National Cancer Data Base

Head and Neck Oncology

High Expression of Nuclear Snail, but not Cytoplasmic Staining, Predicts Poor Survival in Nasopharyngeal Carcinoma

Translational Research and Biomarkers

Clinical Significance of Promoter Hypermethylation of ERβ and RARβ2 in Tumor and Serum DNA in Indian Breast Cancer Patients

Translational Research and Biomarkers

Reduced Expression of PER3 Is Associated with Incidence and Development of Colon Cancer